Prediction of Chemotherapy Response and Patient Prognosis in Non-small Cell Lung Cancer: Dynamic Contrast-enhanced MRI and Diffusion-weighted Imaging Versus Volume-based Parameter of 18F-FDG PET
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Non-small Cell Lung Cancer
- Sponsor
- Samsung Medical Center
- Enrollment
- 35
- Locations
- 1
- Primary Endpoint
- DWI, DCE-MRI, and FDG PET as early predictor for response and prognosis
- Status
- Completed
- Last Updated
- 10 years ago
Overview
Brief Summary
In this prospective study, the investigators will evaluate and compare the usefulness of functional and volumetric informations obtained by 18F-FDG PET and MRI before and after the palliative chemotherapy with the aim of predicting tumor response and prognosis in patients with advanced Non-small Cell Lung Cancer (NSCLC).
Detailed Description
Study cohort will undergo PET/CT and MRI scans prior to chemotherapy and after the first chemotherapy cycle. MRI scans include DCE-MRI and DWI. The following parameters will be calculated using these values: 1. Metabolic parameters on FDG-PET A. SUV change ratio (SCR) = SUVpost/SUVpre B. MTV change ratio (VCR) = MTVpost/pre C. TLG change ratio = SCR X VCR 2. Perfusion parameters on DCE-MRI A. Kep B. K-trans C. ve 3. Diffusion parameters on DWI A. Mean ADC B. fDM
Investigators
Eligibility Criteria
Inclusion Criteria
- •Histologically proven NSCLC
- •Newly diagnosed Stage stage IV
- •Participant is being considered for the chemotherapy with EGFR TKI as a first line therapy
- •At least one measurable primary or other intrathoracic lesion \>= 2cm, according to RECIST
- •Performance status of 0 to 2 on the ECOG scale
- •Age 18 years or older
- •Able to tolerable PET/CT and MRI imaging required by protocol
- •Able to give study-specific informed consent
Exclusion Criteria
- •Pure bronchioloalveolar cell carcinoma histology
- •Thoracic radiotherapy, lung surgery or chemotherapy within three months prior to inclusion in the study
- •Poorly controlled diabetes
- •Prior malignancy
Outcomes
Primary Outcomes
DWI, DCE-MRI, and FDG PET as early predictor for response and prognosis
Time Frame: one year
The primary endpoint of this study is the prediction of one-year overall survival by monitoring the metabolic and functional responses of the tumor following one cycle of chemotherapy.
Secondary Outcomes
- Correlation among DWI, DCE-MRI, and FDG PET and relationship with prognosis(one year)